阿司匹林单药治疗期间发生非心源性卒中后换药:系统评价与网络Meta分析
该系统评价与网络Meta分析纳入9项随机对照试验共5459例阿司匹林治疗期间发生缺血性卒中的患者,比较继续阿司匹林与换用其他抗栓药。换药与继续阿司匹林相比,复发性卒中汇总相对风险为0.88(95%CI 0.76-1.03),复合次要结局为0.89(95%CI 0.72-1.10),均未达统计学显著。
要点
- 阿司匹林治疗期间发生缺血性卒中者,换用其他抗栓药未显著降低复发卒中风险。
- 达比加群、阿哌沙班及阿司匹林加低剂量利伐沙班排名较高,但均未显著优于继续阿司匹林。
- 该高风险人群仍需专门试验确定特定抗栓策略是否真正改善结局。
核心结论
- 阿司匹林治疗期间发生缺血性卒中的患者,换用替代抗栓治疗与继续阿司匹林相比,未 conclusively 降低复发性卒中及复合心血管事件。
研究设计与样本
- 系统评价与网络Meta分析,纳入9项随机对照试验共5459例阿司匹林治疗期间发生缺血性卒中的患者。
- 替代抗栓药包括维生素K拮抗剂2项试验(n=478)、双联抗血小板治疗3项试验(n=2229)、直接口服抗凝药单药3项试验(n=2660)及低剂量直接口服抗凝药加阿司匹林1项试验(n=92)。
- 排除仅报告90天或更短结局的试验及需抗凝的心源性卒中试验。
主要发现
- 复发性缺血性卒中:换药 vs 继续阿司匹林汇总相对风险0.88(95%CI 0.76-1.03),异质性极低(P=0.93;I²=0)。
- 复合次要结局(缺血性卒中、心肌梗死和血管性死亡或全因死亡):6项研究汇总相对风险0.89(95%CI 0.72-1.10)。
- 网络Meta分析中,达比加群、阿哌沙班及阿司匹林加低剂量利伐沙班排名最高,但均未显著优于继续阿司匹林。
- 结局反映中位约19个月(范围11-42个月)的复发事件。
临床怎么用
- 对于阿司匹林治疗期间发生非心源性缺血性卒中的患者,换用替代抗栓药缺乏显著获益证据,决策需个体化。
局限性
- 纳入试验数量有限,部分替代策略样本量较小。
- 中位随访约19个月,长期结局不确定。
- 需专门随机试验验证特定抗栓策略在该高风险人群中的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients who experience an ischemic stroke while on aspirin therapy present a clinical dilemma about optimal long-term secondary prevention. While switching to an alternative antithrombotic agent is often considered, the effectiveness of switching remains uncertain. METHODS: We conducted a systematic review and network meta-analysis of randomized controlled trials reporting outcomes among patients with ischemic stroke while on aspirin who were either continued on aspirin or switched to an alternative antithrombotic therapy. Alternative antithrombotics included 2 trials of vitamin K antagonists (n=478), 3 trials of dual antiplatelet therapy (n=2229), 3 trials of direct oral anticoagulant (n=2660) monotherapy, and 1 trial of low-dose direct oral anticoagulant added onto aspirin (n=92). We excluded trials of patients with only short-term outcomes of 90 days or fewer, or those with cardioembolic sources of stroke requiring anticoagulation. Our primary outcome was recurrent ischemic stroke; the secondary outcome was a composite of ischemic stroke, myocardial infarction, and vascular death (or all-cause mortality). Outcomes reflect recurrent events measured over a median of ≈19 months (range 11-42 months). In the network portion of this meta-analysis, surface under the cumulative ranking curve rankings and pairwise meta-analyses were used to evaluate and compare the relative efficacy of alternative antithrombotic medications. RESULTS: Data were available from 9 studies (total N=5459 patients) for the outcome of recurrent ischemic stroke. Switching to another therapy was associated with a pooled relative risk of recurrent stroke of 0.88 (95% CI, 0.76-1.03) compared with continuing aspirin, with minimal heterogeneity (P=0.93; I²=0). For the composite secondary outcome, 6 studies contributed data, yielding a pooled relative risk of 0.89 (95% CI, 0.72-1.10). In the network meta-analysis, dabigatran, apixaban, and aspirin+low-dose rivaroxaban ranked the highest among antithrombotic alternatives to aspirin, though none were significantly better than continuing aspirin. Rankings were similar when based on posterior estimates from the clinical trials and when using predictive distributions that incorporate between-study variance (ie, expected performance in future settings). CONCLUSIONS: Among patients experiencing ischemic stroke while taking aspirin, switching to an alternative antithrombotic therapy was not conclusively associated with a reduction in recurrent stroke and composite cardiovascular events. Trials are needed to determine whether specific antithrombotic strategies meaningfully improve outcomes in this high-risk population.
引用
- Rothstein A, Khazaal O, Messe SR, et al. Switching From Aspirin Monotherapy After Noncardioembolic Stroke: A Systematic Review and Network Meta-Analysis. Stroke. 2025. PMID: 41347302. doi:10.1161/STROKEAHA.125.053030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。